A multicenter, open label, balanced, randomized, two-treatment, four-period, two sequence, full replicate, single dose, cross-over bioequivalence study of Azacitidine 300 mg film-coated tablets of MSN Laboratories Private Limited, India with that of ONUREG (Azacitidine) 300 mg film-coated tablets of Bristol Myers Squibb Pharma Ireland in adult patients with acute myeloid leukemia (AML) in remission phase under fasting condition. - NIL
A multi-center, open-label, balanced, randomized, two-treatment, two-period, two-sequence, two-way crossover, multiple-dose, steady-state bioequivalence study of Pazopanib HCl Tablets 200 mg (4 Tablets X 200 mg) of MSN Laboratories Private Limited, India compared with Votrient® Tablet 200mg (4 Tablets X 200 mg) of Novartis Pharmaceuticals Corporation, USA in Advanced renal cell carcinoma patients who are already receiving Pazopanib HCl tablets in standard therapy, and who are tolerating a stable dosing regimen of 800 mg/day under fasting conditions. - NIL
Synthesis of novel 1,3,4-oxadiazole derivatives from 1,3-dihydro-1-oxoisobenzofuran-5-carboxylic acid. The structure of the synthesized compounds were confirmed by using IR, 1H NMR, 13C NMR and mass spectroscopy. Further these synthesized derivatives were subjected to biol. activity.
2016·Pharma Chemica
A novel and efficient synthetic route for Pitavastatin calcium
作者: Sahadeva, Reddy M. ; Reddy, M. S. N. ; Rajan, S. T. ; Methuku, Satheesh Kumar ; Chakravarthy, I. E.
A novel and efficient synthetic process developed for Pitavastatin calcium by preparation of key intermediate 2 with high yield and quality by condensing 2-cyclopropyl-4-(4-fluorophenyl)-3-((1-methyl-1H-benzo[d]imidazol-2-ylsulfonyl)methyl) quinoline 13 with (3R,5S)-tert-Bu 3,5-dimethoxy-6-oxohexanoate 10. This synthetic approach efficiently provides highly pure Pitavastatin calcium with high yields.
2016·Pharma Chemica
Structural identification and characterization of impurities in Esmolol hydrochloride
作者: Reddy, M. Sahadev ; Reddy, M. S. N. ; Rajan, S. T. ; Vaka, Srinivas ; Chakravarthy, I. E.
In the synthesis of Esmolol hydrochloride four prominent process impurities were formed during synthesis. These impurities were detected in gradient HPLC method. These impurities are synthesized in different synthesis methods and characterized as 3-(4-(2-hydroxy-3-(iso-Pr amino) propoxy) phenyl)propanoic acid (Esmolol free acid), Me 3-{4- [3-(Et amino)-2-hydroxy propoxy]phenyl} propionate (Esmolol iso-Pr amide analog), 3-(4-(2-hydroxy- 3(isopropylamino)propoxy)phenyl)-N-isopropylpropanamide (N-Et Esmolol), Me 3-(4-(2-hydroxy-3-(3-(4-(2- hydroxy-3-(isopropylamino) propoxy) phenyl)-N-iso-Pr propanamido) propoxy)phenyl)propanoate (Esmolol dimer) by 1H NMR, IR and Mass spectral data. Synthesis and Structural elucidation by spectral data is discussed.